Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25155147 | 1.00 | NOS3 (0.38) | NOS3NOS1NOS2CHRNB4CHRNA3 | |
| SCHEMBL30344494 | 0.88 | SIRT6 (0.37) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL25156029 | 0.86 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL31360053 | 0.86 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL30344681 | 0.86 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL25156314 | 0.86 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL30344086 | 0.86 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL25155441 | 0.86 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL25155906 | 0.81 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL30344911 | 0.81 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | NOS3 1233/4885NOS1 1590/4885NOS2 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.